

**Chiral scandium-complex-catalyzed asymmetric inverse-electron-demand
oxa-Diels–Alder reaction of o-quinone methides with fulvenes**

Jianlin Zhang, Lili Lin,* Changqiang He, Qian Xiong, Xiaohua Liu and Xiaoming Feng*

*Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry,
Sichuan University, Chengdu 610064, P. R. China*

E-mail: xmfeng@scu.edu.cn

lililin@scu.edu.cn

Table of Contents

1. General remarks.....	S2
2. General procedure for catalytic asymmetric [4+2] reaction.....	S2
3. Experimental procedures for the scale-up reaction.....	S2
4. The analytical and spectral characterization data of the products.....	S4
5. The X-ray data for 6d	S26
6. Copy of NMR spectra.....	S27

1. General remarks

Reactions were carried out using commercial available reagents in over-dried apparatus. EtOAc was dried over powdered CaH₂ and distilled under nitrogen just before use. Enantiomeric excesses (*ee*) were determined by HPLC analysis using the corresponding commercial chiral column as stated in the experimental procedures at 23 °C with UV detector at 254 nm. Optical rotations were reported as follows: $[\alpha]_D^{25}$ (c g/100 mL, in solvent). ¹H NMR spectra were recorded on commercial instruments (400 MHz). Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃, δ = 7.26; DMSO, δ = 2.50). Spectra were reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), integration and assignment. ¹³C NMR spectra were collected on commercial instruments (100 MHz) with complete proton decoupling. Chemical shifts are reported in ppm from the tetramethylsilane with the solvent resonance as internal standard (CDCl₃, δ = 77.0; DMSO, δ = 39.5). HRMS was recorded on a commercial apparatus (ESI Source).


2. General procedure for catalytic asymmetric [4+2] reaction

Preparation of the chiral catalyst: *N,N'*-dioxide **L-PrAd** (0.105 mmol) and Sc(OTf)₃ (0.1 mmol) were stirred in 2 mL EtOAc at 25 °C for 16 h, and then dried under high vacuum.

General procedure for catalytic asymmetric reaction, Condition A: A dry reaction tube was charged with **L-PrAd**-Sc(OTf)₃ (1.05:1, 10 mol% catalyst loading), and *o*-QMs **1** (0.15 mmol). Then, EtOAc (0.5 mL) was added and the mixture was stirred at 25 °C for 0.5 h. Then, the reaction temperature was reduced to 0 °C, and fulvene **2** (0.1 mmol) was added. The reaction mixture was stirred for 48 h. The residue was purified by flash chromatography (petroleum ether/ethyl acetate 19:1) on silica gel to afford the product. The enantiomeric excess (*ee*) was determined by high-performance liquid chromatography (HPLC).

General procedure for catalytic asymmetric reaction, Condition B: A dry reaction tube was charged with **L-PrAd**-Sc(OTf)₃ (1.05:1, 10 mol% catalyst loading), and *o*-QMs **4** (0.15 mmol). Then, EtOAc (0.5 mL) was added and the mixture was stirred at 25 °C for 0.5 h. Then, the reaction temperature was reduced to 0 °C, and fulvene **5** (0.1 mmol) was added. After stirred at 0 °C for 24 h, the reaction mixture was raised to 25 °C for 24 h. The residue was purified by flash chromatography (petroleum ether/ethyl acetate 19:1) on silica gel to afford the product. The enantiomeric excess (*ee*) was determined by high-performance liquid chromatography (SFC).


3. General procedure for the scale-up reaction.




Typical procedure for the scale-up reaction: A flask (50 mL) was charged with **L-PrAd-Sc(OTf)₃** (1.05:1, 10 mol% catalyst loading) and **1a** (4.5 mmol, 1.215 g). Then, EtOAc (15 mL) was added and the mixture was stirred at 25 °C for 0.5 h. Then, the reaction temperature was reduced to 0 °C, and fulvene **2a** (3.0 mmol, 0.354g) was added. The reaction mixture was stirred for 48 h. The residue was purified by flash chromatography (petroleum ether/ethyl acetate 19:1) on silica gel to afford the product **3aa** as a foamed solid (1.153 g, 99% yield, 92% ee).

4. The analytical and spectral characterization data of the products


(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-4-fluorostyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (**3aa**) :



Prepared according to the general procedure, Condition A. The title compound **3aa** was obtained as yellow oil in 38.1 mg, 98% yield, >19:1 dr, 91% ee. HPLC (Chiralcel ID, hexane/*i*-PrOH = 95/5, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 7.49 min, t_r (minor) = 6.20 min. $[\alpha]^{16.4}_D = +277.5$ (c = 0.35, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.26 – 7.18 (m, 2H), 7.00 – 6.89 (m, 2H), 6.62 (s, 1H), 6.54 (s, 1H), 6.32 (dd, J = 5.6, 1.2 Hz, 1H), 6.26 (d, J = 16.0 Hz, 1H), 6.15 (dd, J = 15.6, 8.8 Hz, 1H), 5.98 (d, J = 5.6 Hz, 1H), 5.89 (dd, J = 5.6, 1.6 Hz, 2H), 5.24 (d, J = 7.6 Hz, 1H), 3.62 (dd, J = 8.4, 7.2 Hz, 1H), 3.32 (t, J = 7.2 Hz, 1H), 2.95-2.63 (m, 4H), 2.13 – 1.93 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ = 163.1, 160.7, 149.8, 146.6, 142.4, 134.9, 134.8, 134.5, 133.8, 133.8, 131.8, 129.3, 129.2, 128.6, 127.6, 127.6, 124.0, 115.3, 115.1, 107.1, 100.9, 100.6, 85.4, 46.2, 43.1, 30.6, 30.3, 17.6. IR $\tilde{\nu}$ (film): 2951, 2906, 1508, 1477, 1446, 1257, 1224, 1147, 1039, 966, 939, 858, 823. HRMS (ESI-TOF) calcd for $\text{C}_{25}\text{H}_{21}\text{O}_3\text{FK}^+$ ($[\text{M}]+\text{K}^+$) = 427.1106, Found 427.1111.




	Retention Time	Area	% Area
1	5.851	13604358	50.01
2	6.941	13599188	49.99




	Retention Time	Area	% Area
1	6.206	41286	4.61
2	7.495	854366	95.39

(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-styryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (**3ba**) :




Prepared according to the general procedure, Condition A. The title compound **3ba** was obtained as yellow oil in 36.0 mg, 97% yield, >19:1 dr, 91% ee. HPLC (Chiralcel ID, hexane/*i*-PrOH = 95/5, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 6.87 min, t_r (minor) = 6.20 min. $[\alpha]^{16.3}_D = +266.3$ (c = 0.65, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.25-7.10

(m, 4H), 7.11-7.05 (m, 1H), 6.55 (s, 1H), 6.46 (s, 1H), 6.28 – 6.20 (m, 2H), 6.16 (dd, $J = 15.6, 8.4$ Hz, 1H), 5.89 (d, $J = 5.2$ Hz, 1H), 5.80 (dd, $J = 6.0, 1.2$ Hz, 2H), 5.17 (d, $J = 7.2$ Hz, 1H), 3.60 – 3.51 (m, 1H), 3.25 (t, $J = 7.2$ Hz, 1H), 2.85 – 2.54 (m, 4H), 2.02 – 1.86 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 149.8, 146.6, 142.4, 137.7, 134.9, 134.9, 134.5, 131.8, 129.9, 129.5, 128.3, 127.1, 126.9, 126.2, 124.1, 107.2, 100.9, 100.5, 85.4, 46.2, 43.2, 30.7, 30.4, 17.6$. IR $\tilde{\nu}$ (film): 2951, 2908, 1500, 1479, 1448, 1261, 1149, 1037, 964, 935, 864, 839, 754. HRMS (ESI-TOF) calcd for $\text{C}_{25}\text{H}_{22}\text{O}_3\text{K}^+$ ($[\text{M}]+\text{K}^+$) = 409.1201, Found 409.1200.




	Retention Time	Area	% Area
1	6.197	3055884	50.49
2	6.874	2997004	49.51




	Retention Time	Area	% Area
1	6.221	31806	4.43
2	6.898	685517	95.57


(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-4-methoxystyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ca) :



Prepared according to the general procedure, Condition A. The title compound **3ca** was obtained as yellow oil in 38.2 mg, 95% yield, >19:1 dr, 91% ee. HPLC (Chiralcel ID, hexane/*i*-PrOH = 95/5, flow rate 1.0 mL/min, $\lambda = 254$ nm) t_r (major) = 21.47 min, t_r (minor) = 25.41 min. $[\alpha]_D^{17.0} = +247.5$ ($c = 0.37$, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.25-7.18 (m, 2H), 6.84-6.76 (m, 2H), 6.63 (s, 1H), 6.53 (s, 1H), 6.31 (dd, $J = 5.6, 1.2$ Hz, 1H), 6.26 (d, $J = 15.6$ Hz, 1H), 6.10 (dd, $J = 15.6, 8.8$ Hz, 1H), 5.96 (d, $J = 5.2$ Hz, 1H), 5.88 (dd, $J = 5.6, 1.6$ Hz, 2H), 5.26 (d, $J = 7.6$ Hz, 1H), 3.78 (s, 3H), 3.61 (dd, $J = 8.8, 7.2$ Hz, 1H), 3.33 (t, $J = 7.6$ Hz, 1H), 2.93 – 2.58 (m, 4H), 2.09 – 1.93 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 158.7, 149.7, 146.5, 142.4, 135.0, 134.9, 134.5, 134.0, 131.8, 130.5, 129.3, 127.3, 127.3, 124.3, 113.8, 107.1, 100.9, 100.5, 85.4, 55.2, 46.3, 43.1, 30.8, 30.4, 17.6$. IR $\tilde{\nu}$ (film): 2953, 2908, 1606, 1508, 1479, 1450, 1247, 1151, 1035, 966, 937, 829. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{24}\text{O}_4\text{K}^+$ ($[\text{M}]+\text{K}^+$) = 439.1306, Found 439.1318.




	Retention Time	Area	% Area
1	21.467	3851515	49.65
2	25.406	3906102	50.35




	Retention Time	Area	% Area
1	21.371	2099489	95.79
2	25.937	92320	4.21

(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-4-methylstyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3da) :




Prepared according to the general procedure, Condition A. The title compound **3da** was obtained as yellow oil in 36.4 mg, 95% yield, >19:1 dr, 91% ee. HPLC (Chiralcel ID, hexane/*i*-PrOH = 95/5, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 7.47 min, t_r (minor) = 6.05 min. $[\alpha]_D^{16.6} = +242.8$ (c = 0.59, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.19 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 6.63 (s, 1H), 6.54 (s, 1H), 6.35-6.25 (m, 2H), 6.19 (dd, J = 15.6, 8.8 Hz, 1H), 5.97 (d, J = 5.2 Hz, 1H), 5.88 (dd, J = 5.2, 1.2 Hz, 2H), 5.26 (d, J = 7.6 Hz, 1H), 3.62 (dd, J = 8.4, 7.2 Hz, 1H), 3.34 (t, J = 7.2 Hz, 1H), 2.98 – 2.63 (m, 4H), 2.31 (s, 3H), 2.09 – 1.95 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ = 149.8, 146.5, 142.4, 136.6, 134.9, 134.9, 134.5, 131.8, 129.8, 129.0, 128.4, 126.1, 124.2, 107.1, 100.9, 100.5, 85.4, 46.3, 43.2, 30.7, 30.4, 21.1, 17.6. IR $\tilde{\nu}$ (film): 2943, 2908, 1500, 1475, 1450, 1263, 1147, 1039, 962, 935, 860, 808. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{24}\text{O}_3\text{H}^+$ ($[\text{M}] + \text{H}^+$) = 383.1653, Found 383.1644.




	Retention Time	Area	% Area
1	6.052	2444146	50.77

2	7.474	2369550	49.23
---	-------	---------	-------




	Retention Time	Area	% Area
1	6.060	53476	4.43
2	7.493	1153191	95.57


(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-3-methylstyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ea) :



Prepared according to the general procedure, Condition A. The title compound **3ea** was obtained as yellow oil in 37.6 mg, 98% yield, >19:1 dr, 91% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 7.11 min, t_r (minor) = 5.30 min. $[\alpha]_D^{16.9}$ = +279.1 (c = 0.64, in CH_2Cl_2). ^{13}C NMR (100 MHz, CDCl_3) δ = 149.98, 146.61, 142.44, 136.94, 135.29, 134.91, 134.85, 134.34, 131.90, 130.97, 129.97, 127.82, 126.87, 126.11, 125.94, 124.23, 107.22, 100.94, 100.56, 85.45, 46.31, 43.72, 30.64, 30.35, 19.80, 17.57. ^{13}C NMR (100 MHz, CDCl_3) δ = 149.8, 146.6, 142.4, 137.9, 137.6, 135.0, 134.5, 131.7, 130.0, 129.2, 128.2, 127.7, 126.9, 124.2, 123.4, 107.2, 100.9, 100.5, 85.4, 46.2, 43.3, 30.7, 30.4, 21.3, 17.6. IR $\tilde{\nu}$ (film): 2951, 2910, 1502, 1475, 1450, 1259, 1151, 1085, 1039, 962, 937, 856, 773, 736. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{24}\text{O}_3\text{H}^+$ ($[\text{M}]+\text{H}^+$) = 383.1653, Found 383.1646.




	Retention Time	Area	% Area
1	5.326	664092	50.96
2	7.132	638992	49.04




	Retention Time	Area	% Area
1	5.300	516425	4.63

2	7.118	10634293	95.37
---	-------	----------	-------


(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-2-methylstyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3fa) :



Prepared according to the general procedure, Condition A. The title compound **3fa** was obtained as yellow oil in 36.8 mg, 96% yield, >19:1 dr, 95% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 6.57 min, t_r (minor) = 5.09 min. $[\alpha]^{16.8}_D = +268.7$ (c = 0.40, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.31 – 7.26 (m, 1H), 7.09 (m, 3H), 6.65 (s, 1H), 6.55 (s, 1H), 6.51 (d, J = 15.6 Hz, 1H), 6.32 (dd, J = 5.6, 1.2 Hz, 1H), 6.07 (dd, J = 15.6, 9.6 Hz, 1H), 5.99 (d, J = 5.6 Hz, 1H), 5.89 (dd, J = 4.0, 1.6 Hz, 2H), 5.24 (dd, J = 7.6, 0.8 Hz, 1H), 3.66 (dd, J = 9.2, 6.8 Hz, 1H), 3.34 (t, J = 7.2 Hz, 1H), 2.97 – 2.67 (m, 4H), 2.31 (s, 3H), 2.14 – 1.93 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ = 149.9, 146.6, 142.4, 136.9, 135.2, 134.9, 134.8, 134.3, 131.9, 130.9, 129.9, 127.8, 126.8, 126.1, 125.9, 124.2, 107.2, 100.9, 100.5, 85.4, 46.3, 43.7, 30.6, 30.3, 19.8, 17.5. IR $\tilde{\nu}$ (film): 2947, 2910, 1500, 1477, 1446, 1263, 1145, 1082, 1039, 966, 937, 860, 754. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{24}\text{O}_3\text{H}^+$ ($[\text{M}] + \text{H}^+$) = 383.1653, Found 383.1644.




	Retention Time	Area	% Area
1	5.089	5895564	49.36
2	6.570	6048273	50.64




	Retention Time	Area	% Area
1	5.059	50717	2.51
2	6.547	1971682	97.49

(5a*S*,8a*R*,9*R*)-8-cyclobutylidene-9-((*E*)-2-(thiophen-3-yl)vinyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ga) :




Prepared according to the general procedure, Condition A. The title compound **3ga** was obtained as yellow oil in 36.4 mg, 97% yield, >19:1 dr, 90% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 9.88 min, t_r (minor) = 6.64 min. $[\alpha]^{17.1}_D = +264.7$ (c = 0.71, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.23-7.17

(m, 1H), 7.12 (dd, $J = 5.2, 0.8$ Hz, 1H), 7.06 – 6.99 (m, 1H), 6.62 (s, 1H), 6.54 (s, 1H), 6.36 – 6.27 (m, 2H), 6.11 (dd, $J = 15.6, 8.8$ Hz, 1H), 5.96 (d, $J = 5.2$ Hz, 1H), 5.88 (dd, $J = 5.6, 1.6$ Hz, 2H), 5.25 (d, $J = 7.6$ Hz, 1H), 3.63 – 3.54 (m, 1H), 3.33 (t, $J = 7.6$ Hz, 1H), 2.92 – 2.64 (m, 4H), 2.13 – 1.95 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 149.8, 146.6, 142.4, 140.2, 134.9, 134.5, 131.8, 129.4, 125.6, 125.3, 124.2, 124.1, 120.9, 107.1, 100.9, 100.5, 85.4, 46.2, 43.1, 30.7, 30.4, 17.6$. IR $\tilde{\nu}$ (film): 2949, 2904, 1498, 1477, 1450, 1257, 1151, 1080, 1037, 962, 937, 860, 769. HRMS (ESI-TOF) calcd for $\text{C}_{23}\text{H}_{20}\text{O}_3\text{SNa}^+$ ($[\text{M}]+\text{Na}^+$) = 399.1025, Found 399.1032.




	Retention Time	Area	% Area
1	6.642	2644741	50.10
2	9.883	2634693	49.90




	Retention Time	Area	% Area
1	6.588	1747648	4.79
2	9.791	34720377	95.21


(5a*S*,8a*R*,9*R*)-8-cyclopentylidene-9-((*E*)-4-fluorostyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ab) :



Prepared according to the general procedure, Condition A. The title compound **3ab** was obtained as yellow oil in 38.6 mg, 96% yield, >19:1 dr, 92% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, $\lambda = 254$ nm) t_r (major) = 7.52 min, t_r (minor) = 5.88 min. $[\alpha]_D^{17.2} = +255.8$ ($c = 0.62$, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.12 (m, 2H), 6.98–6.86 (m, 2H), 6.64 (s, 1H), 6.56 (s, 1H), 6.46 (dd, $J = 5.6, 1.2$ Hz, 1H), 6.13 (d, $J = 8.0$ Hz, 2H), 6.05 (d, $J = 5.2$ Hz, 1H), 5.90 (dd, $J = 5.6, 1.2$ Hz, 2H), 5.25 (d, $J = 7.2$ Hz, 1H), 3.76 (t, $J = 7.2$ Hz, 1H), 3.31 (t, $J = 7.2$ Hz, 1H), 2.34 (dd, $J = 21.1, 14.0$ Hz, 4H), 1.82 – 1.58 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 163.1, 160.6, 149.9, 146.7, 142.4, 136.7, 136.3, 134.5, 133.8, 133.8, 132.1, 129.3, 129.3, 128.2, 127.6, 127.5, 123.8, 115.2, 115.0, 107.4, 100.9, 100.4, 85.4, 47.8, 42.6, 31.3, 31.0, 26.7, 26.4$. IR $\tilde{\nu}$ (film): 2951, 2868, 1602, 1506, 1479, 1448, 1228, 1147, 1056, 1035, 966, 935, 842, 819, 740. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{23}\text{O}_3\text{FK}^+$ ($[\text{M}]+\text{K}^+$) = 441.1263, Found 441.1270.




	Retention Time	Area	% Area
1	5.884	2219652	49.87
2	7.518	2231665	50.13




	Retention Time	Area	% Area
1	5.899	157674	3.77
2	7.548	4024883	96.23


(5a*S*,8a*R*,9*R*)-8-cyclohexylidene-9-((*E*)-4-fluorostyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ac) :



Prepared according to the general procedure, Condition A. The title compound **3ac** was obtained as yellow oil in 40.3 mg, 97% yield, >19:1 dr, 93% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 6.95 min, t_r (minor) = 5.61 min. $[\alpha]^{17.5}_D = +274.4$ (c = 0.71, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.15 – 7.04 (m, 2H), 6.86-6.77 (m, 2H), 6.55 (s, 1H), 6.51 (dd, J = 5.6, 1.6 Hz, 1H), 6.47 (s, 1H), 6.29 (s, 0.05H), 6.04 (d, J = 6.8 Hz, 2H), 5.99 (dd, J = 5.6, 1.6 Hz, 1H), 5.81 (dd, J = 5.6, 1.6 Hz, 2H), 5.20 (d, J = 7.6 Hz, 1H), 3.53 (t, J = 6.4 Hz, 1H), 3.32 (t, J = 7.2 Hz, 1H), 2.33 – 2.04 (m, 4H), 1.63 – 1.34 (m, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ = 163.1, 160.6, 149.9, 146.7, 142.3, 135.1, 134.3, 133.8, 133.8, 133.6, 133.0, 129.0, 128.9, 128.6, 127.6, 127.5, 123.5, 115.2, 115.0, 107.3, 100.9, 100.3, 84.7, 46.5, 44.6, 31.9, 31.5, 28.2, 28.0, 26.7. IR $\hat{\nu}$ (film): 2927, 2854, 1602, 1506, 1477, 1444, 1224, 1147, 1072, 1039, 962, 937, 848, 823, 736. HRMS (ESI-TOF) calcd for $\text{C}_{27}\text{H}_{25}\text{O}_3\text{FK}^+$ ($[\text{M}]+\text{K}^+$) = 455.1419, Found 455.1428.




	Retention Time	Area	% Area
1	5.618	2003465	51.00
2	6.951	1924707	49.00




	Retention Time	Area	% Area
--	----------------	------	--------

1	5.619	39327	3.28
2	6.950	1157868	96.72


(5a*S*,8a*R*,9*R*)-9-((*E*)-4-fluorostyryl)-8-(tetrahydro-4*H*-pyran-4-ylidene)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ad) :



Prepared according to the general procedure, Condition A. The title compound **3ad** was obtained as yellow oil in 40.1 mg, 96% yield, >19:1 dr, 94% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 9.72 min, t_r (minor) = 11.11 min. $[\alpha]^{17.3}_D = +278.1$ (c = 0.86, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.13 (m, 2H), 6.96-6.87 (m, 2H), 6.61 (s, 1H), 6.59 – 6.53 (m, 2H), 6.23 – 6.13 (m, 2H), 6.08 (dd, J = 15.6, 8.8 Hz, 2H), 5.89 (dd, J = 7.6, 1.6 Hz, 2H), 5.28 (d, J = 7.6 Hz, 1H), 3.88-3.79 (m, 1H), 3.79-3.71 (m, 1H), 3.65 (t, J = 5.6 Hz, 2H), 3.60 (dd, J = 8.4, 6.8 Hz, 1H), 3.42 (t, J = 7.2 Hz, 1H), 2.52 – 2.40 (m, 2H), 2.37 (t, J = 5.6 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ = 163.2, 160.7, 149.8, 146.9, 142.4, 137.0, 134.2, 133.7, 133.5, 128.8, 128.5, 128.4, 127.7, 127.6, 127.5, 123.2, 115.3, 115.1, 107.2, 101.0, 100.4, 84.5, 69.0, 68.6, 46.4, 44.7, 32.3, 31.8. IR $\tilde{\nu}$ (film): 2960, 2846, 1600, 1508, 1475, 1444, 1222, 1151, 1095, 1035, 964, 927, 848, 815, 734. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{23}\text{O}_4\text{FK}^+$ ($[\text{M}] + \text{K}^+$) = 457.1212, Found 457.1214.




	Retention Time	Area	% Area
1	9.716	1563555	50.87
2	11.109	1510300	49.13




	Retention Time	Area	% Area
1	9.561	6742171	96.73
2	10.980	227972	3.27

(5a*S*,8a*R*,9*R*)-8-cycloheptylidene-9-((*E*)-4-fluorostyryl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3ae) :




Prepared according to the general procedure, Condition A. The title compound **3ae** was obtained as yellow oil in 42.1 mg, 98% yield, >19:1 dr, 93% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 6.67 min, t_r (minor) = 5.68 min.

$[\alpha]_{\text{D}}^{17.6} = +281.6$ ($c = 0.61$, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.19 – 7.12 (m, 2H), 6.95-6.86 (m, 2H), 6.64 (s, 1H), 6.60 (dd, $J = 5.6, 1.6$ Hz, 1H), 6.55 (s, 1H), 6.13 (d, $J = 3.6$ Hz, 2H), 6.08 (dd, $J = 5.6, 1.6$ Hz, 1H), 5.90 (dd, $J = 5.2, 1.6$ Hz, 2H), 5.27 (d, $J = 7.6$ Hz, 1H), 3.74 – 3.67 (m, 1H), 3.37 (t, $J = 6.8$ Hz, 1H), 2.50-2.42 (m, 2H), 2.35 (d, $J = 4.4$ Hz, 2H), 1.80-1.68 (m, 2H), 1.64 – 1.47 (m, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ = 163.0, 160.6, 149.9, 146.7, 142.3, 137.8, 135.2, 134.8, 133.8, 133.8, 132.8, 129.1, 128.4, 127.5, 127.5, 123.5, 115.2, 115.0, 107.4, 100.9, 100.3, 85.0, 47.1, 43.8, 33.2, 31.9, 29.9, 28.9, 28.4, 27.5. IR $\tilde{\nu}$ (film): 2920, 2854, 1598, 1506, 1475, 1448, 1224, 1153, 1070, 1037, 962, 939, 846, 817, 736. HRMS (ESI-TOF) calcd for $\text{C}_{28}\text{H}_{27}\text{O}_3\text{FK}^+$ ($[\text{M}]+\text{K}^+$) = 469.1576, Found 469.1587.




	Retention Time	Area	% Area
1	5.678	3123224	50.27
2	6.668	3089623	49.73




	Retention Time	Area	% Area
1	5.675	630931	3.56
2	6.652	17100282	96.44


(5a*S*,8a*R*,9*R*)-9-((*E*)-4-fluorostyryl)-8-(propan-2-ylidene)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3af) :



Prepared according to the general procedure, Condition A. The title compound **3af** was obtained as yellow oil in 37.2 mg, 99% yield, >19:1 dr, 93% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, $\lambda = 254$ nm) t_{r} (major) = 7.47 min, t_{r} (minor) = 6.02 min. $[\alpha]_{\text{D}}^{17.7} = +277.5$ ($c = 0.45$, in CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.22 – 7.11 (m, 2H), 6.98 – 6.87 (m, 2H), 6.64 (s, 1H), 6.60 – 6.54 (m, 2H), 6.11 (d, $J = 7.6$ Hz, 2H), 6.08-6.04 (m, 1H), 5.90 (dd, $J = 5.6, 1.2$ Hz, 2H), 5.27 (d, $J = 7.6$ Hz, 1H), 3.71 (t, $J = 6.8$ Hz, 1H), 3.39 (t, $J = 7.2$ Hz, 1H), 1.87 (s, 3H), 1.79 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ = 163.1, 160.6, 149.9, 146.7, 142.3, 138.0, 135.0, 133.8, 133.8, 132.7, 129.1, 129.1, 128.3, 127.6, 127.5, 125.2, 123.6, 115.2, 115.0, 107.3, 100.9, 100.4, 85.0, 47.2, 43.9, 29.7, 21.5, 20.9. IR $\tilde{\nu}$ (film): 2906, 1598, 1508, 1481, 1448, 1373, 1257, 1222, 1147, 1041, 966, 937, 840, 817, 738. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{O}_3\text{FK}^+$ ($[\text{M}]+\text{K}^+$) = 415.1106, Found 415.1113.




	Retention Time	Area	% Area
1	6.024	1896060	49.00
2	7.467	1973760	51.00




	Retention Time	Area	% Area
1	5.983	416420	3.64
2	7.437	11034338	96.36


(5a*S*,8a*R*,9*R*)-9-((*E*)-4-fluorostyryl)-8-(pentan-3-ylidene)-5a,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (3a*g*) :



Prepared according to the general procedure, Condition A. The title compound **3a*g*** was obtained as yellow oil in 39.2 mg, 97% yield, >19:1 dr, 93% ee. HPLC (Chiralcel IB, hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm) t_r (major) = 6.33 min, t_r (minor) = 5.42 min. $[\alpha]_D^{17.6}$ = +261.2 (c = 1.17, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.11 (m, 2H), 6.95–6.86 (m, 2H), 6.64 (s, 1H), 6.56 (m, 2H), 6.10 (m, 3H), 5.90 (dd, J = 5.2, 1.2 Hz, 2H), 5.27 (d, J = 7.6 Hz, 1H), 3.69–3.62 (m, 1H), 3.39 (t, J = 7.2 Hz, 1H), 2.36 – 2.06 (m, 4H), 1.11 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 163.0, 160.6, 149.9, 146.8, 142.3, 137.2, 137.1, 134.6, 133.7, 133.7, 133.4, 128.8, 128.8, 128.5, 127.5, 127.5, 123.3, 115.2, 115.0, 107.4, 105.9, 100.9, 100.3, 98.9, 84.7, 46.5, 44.4, 25.4, 24.3, 14.1, 12.9. IR $\tilde{\nu}$ (film): 2962, 2935, 2873, 1506, 1475, 1228, 1147, 1037, 962, 941, 837, 817. HRMS (ESI-TOF) calcd for C₂₆H₂₅O₃FK⁺ ([M]⁺+K⁺) = 443.1419, Found 443.1425.




	Retention Time	Area	% Area
1	5.421	3402986	48.49
2	6.330	3615560	51.51




	Retention Time	Area	% Area
1	5.451	171020	3.36
2	6.355	4915994	96.64


(5a*S*,8a*R*,9*S*)-8-benzylidene-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6a):



Prepared according to the general procedure, Condition B. The title compound **6a** was obtained as yellow oil in 34.9 mg, 85% yield, *E/Z* = 3:1, 90/86% ee. SFC (Chiralcel Lux 5 μ Cellulose-1, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) t_1 = 19.73 min, t_2 = 23.23 min, t_3 = 24.76 min, t_4 = 31.92 min. ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.37 (m, 1.34H), 7.32 – 7.27 (m, 1.30H), 7.22 – 7.13 (m, 2H), 7.12 – 7.06 (m, 1.39H), 6.78 – 6.66 (m, 2H), 6.65 – 6.58 (m, 2.29H), 6.56 – 6.49 (m, 1H), 6.29 (s, 0.34H), 6.22 – 6.16 (m, 1.31H), 6.11 (s, 0.72H), 5.93 – 5.81 (m, 2H), 5.50 – 5.40 (m, 1H), 4.25 – 4.18 (m, 1H), 4.15 (t, *J* = 7.6 Hz, 0.35H), 3.73 (s, 2H), 3.69 (s, 1H), 3.62 (t, *J* = 7.6 Hz, 0.72H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.0, 157.8, 149.7, 149.2, 146.8, 146.7, 146.6, 145.3, 142.4, 139.9, 138.7, 137.8, 137.7, 134.9, 134.2, 132.9, 132.0, 130.9, 130.0, 128.6, 128.3, 128.1, 126.8, 126.5, 123.7, 123.4, 123.4, 123.1, 112.8, 112.5, 108.1, 107.8, 101.0, 100.4, 100.3, 85.3, 83.2, 55.1, 55.0, 49.2, 46.2, 45.4, 42.6. IR $\tilde{\nu}$ (film): 2914, 1510, 1475, 1251, 1178, 1149, 1068, 1033, 935, 860. HRMS (ESI-TOF) calcd for C₂₇H₂₂KO₄⁺ ([M]⁺+K⁺) = 449.1150, Found 449.1147.




	Retention Time	Area	% Area
1	19.680	732660	12.71
2	23.155	1943306	33.70
3	24.782	752780	13.06
4	28.690	210174	3.65
5	29.465	206036	3.57
6	32.015	1920789	33.31




	Retention Time	Area	% Area
1	19.735	648944	1.94
2	23.231	1243365	3.71
3	24.767	8674008	25.91
4	31.920	22916747	68.44

(5a*S*,8a*R*,9*S*)-8-(4-fluorobenzylidene)-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6b) :




Prepared according to the general procedure, Condition B. The title compound **6b** was obtained as yellow oil in 31.2 mg, 73% yield, *E/Z* = 1.5:1, 90/90% ee. SFC (Chiralcel Lux 5 μ Cellulose-3, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 9.62 min, *t*₂ = 10.64 min, *t*₃ = 13.13 min, *t*₄ = 15.90 min. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.30 (m, 0.88H), 7.18 – 7.07 (m, 2H), 7.06 – 7.00 (m, 1.17H), 6.99 –

6.92 (m, 1.16H), 6.78 – 6.72 (m, 0.89H), 6.72 – 6.66 (m, 1.16H), 6.64 – 6.58 (m, 1.51H), 6.56 – 6.49 (m, 1.83H), 6.23 (s, 0.43H), 6.22 – 6.16 (m, 1.37H), 6.03 (s, 0.57H), 5.92 – 5.82 (m, 2H), 5.48 – 5.38 (m, 1H), 4.22 – 4.13 (m, 1H), 4.09 (td, *J* = 7.6, 2.0 Hz, 0.43H), 3.73 (s, 1.72H), 3.69 (s, 1.22H), 3.61 (td, *J* = 7.6, 2.0 Hz, 0.60H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.7, 160.3, 158.0, 157.9, 149.6, 149.1, 146.8, 146.8, 146.4, 145.2, 142.4, 142.4, 139.8, 138.9, 134.9, 133.9, 133.8, 133.8, 132.9, 132.0, 130.9, 129.9, 129.8, 129.7, 129.6, 129.5, 123.6, 123.3, 122.2, 122.0, 115.7, 115.5, 115.3, 115.1, 112.8, 112.6, 108.0, 107.8, 101.0, 100.4, 100.3, 85.2, 83.2, 55.1, 55.0, 49.0, 46.1, 45.1, 42.7. IR $\tilde{\nu}$ (film): 2895, 1506, 1475, 1249, 1180, 1145, 1066, 1035, 939, 858. HRMS (ESI-TOF) calcd for C₂₇H₂₁O₄K⁺ ([M]⁺+K⁺) = 467.1055, Found 467.1065.




	Retention Time	Area	% Area
1	9.616	359778	12.96
2	10.643	341546	12.31
3	13.127	1048114	37.77
4	15.901	1025788	36.96



	Retention Time	Area	% Area
1	9.464	359639	1.97
2	10.442	6751508	37.00
3	12.972	625518	3.43
4	15.592	10509368	57.60


(5a*S*,8a*R*,9*S*)-8-(4-chlorobenzylidene)-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6c) :




Prepared according to the general procedure, Condition B.

The title compound **6c** was obtained as yellow oil in 40.4 mg, 91% yield, *E/Z* = 1.5:1, 95/93% ee. SFC (Chiralcel Lux 5 μ Amylose-2, CO₂/i-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 19.19 min, *t*₂ = 22.11 min, *t*₃ = 25.70 min, *t*₄ = 32.02 min. ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.35 (m, 0.78H), 7.33 – 7.28 (m, 0.78H), 7.26 – 7.20 (m, 1.22H), 7.16

– 7.10 (m, 1.22H), 7.03 – 6.98 (m, 1.22H), 6.78 – 6.73 (m, 0.80H), 6.72 – 6.66 (m, 1.25H), 6.61 (d, *J* = 6.4 Hz, 1.59H), 6.57 – 6.49 (m, 1.75H), 6.26 – 6.16 (m, 1.76H), 6.01 (s, 0.63H), 5.91-5.88 (m, 1H), 5.86 (d, *J* = 1.2 Hz, 0.61H), 5.83 (d, *J* = 1.2 Hz, 0.37H), 5.50-5.38 (m, 1H), 4.23 – 4.15 (m, 1H), 4.10 (td, *J* = 7.2, 1.6 Hz, 0.38H), 3.73 (s, 1.86H), 3.69 (s, 1.11H), 3.61 (td, *J* = 7.2, 1.6 Hz, 0.61H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.1, 157.9, 149.6, 149.1, 147.3, 146.9, 146.8, 145.9, 142.4, 142.4, 139.8, 139.4, 136.2, 136.2, 135.5, 133.8, 132.8, 132.3, 132.1, 131.9, 130.9, 129.9, 129.5, 129.3, 128.8, 128.4, 123.5, 123.2, 122.1, 121.9, 112.8, 112.6, 108.0, 107.8, 101.0, 100.4, 100.3, 85.1, 83.1, 55.1, 55.0, 49.2, 46.1, 45.3, 42.7. IR $\hat{\nu}$ (film): 2900, 1510, 1475, 1251, 1178, 1145, 1066, 1035, 937, 856. HRMS (ESI-TOF) calcd for C₂₇H₂₁Cl^{34.9689}O₄K⁺ ([M]⁺+K⁺) = 483.0760, Found 483.0766; calcd for C₂₇H₂₁Cl^{36.9659}O₄K⁺ ([M]⁺+K⁺) = 485.0730, Found 485.0732.




	Retention Time	Area	% Area
1	19.195	1467129	15.28
2	22.110	1415335	14.74
3	25.704	3345324	34.84
4	32.022	3373864	35.14




	Retention Time	Area	% Area
1	19.208	2279860	30.96
2	22.321	85008	1.15
3	25.754	4874218	66.20
4	32.282	124124	1.69

(5a*S*,8a*R*,9*S*)-8-(4-bromobenzylidene)-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6d) :




Prepared according to the general procedure, Condition B. The title compound **6d** was obtained as yellow oil in 45.8 mg, 94% yield, *E/Z* = 2.3:1, 96/90% ee. SFC (Chiralcel Lux 5 μ Amylose-2, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 23.08 min, *t*₂ = 27.09 min, *t*₃ = 30.65 min, *t*₄ = 34.83 min. ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, *J* = 8.4 Hz, 0.7H), 7.38 (d, *J* = 8.4 Hz, 1.3H), 7.24 (d, *J* = 8.4 Hz, 0.7H),

7.12 (d, *J* = 8.4 Hz, 1.3H), 6.94 (d, *J* = 8.4 Hz, 1.3H), 6.74 (d, *J* = 8.7 Hz, 0.7H), 6.71 – 6.65 (m, 1.3H), 6.60 (d, *J* = 7.2 Hz, 1.6H), 6.53 (m, 1.6H), 6.24 – 6.16 (m, 1.6H), 5.99 (s, 0.7H), 5.87 (m, 2H), 5.43 (d, *J* = 7.2 Hz, 1H), 4.17 (dd, *J* = 7.6, 3.6 Hz, 1H), 4.09 (m, 0.3H), 3.73 (s, 2H), 3.69 (s, 1H), 3.64 – 3.57 (m, 0.7H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.1, 157.9, 149.6, 149.0, 147.4, 146.8, 146.0, 142.4, 139.8, 139.5, 136.6, 135.6, 133.8, 132.7, 131.9, 131.7, 131.4, 130.9, 129.9, 129.8, 129.6, 123.2, 122.1, 121.9, 120.4, 120.3, 112.8, 112.6, 108.0, 107.8, 101.0, 100.4, 100.3, 85.1, 83.1, 55.1, 49.2, 46.1, 45.3, 42.6. IR $\tilde{\nu}$ (film): 2893, 1508, 1475, 1251, 1182, 1149, 1068, 1033, 939, 856. HRMS (ESI-TOF) calcd for C₂₇H₂₁Br^{78.9183}O₃K⁺ ([M]+K⁺) = 527.0255, Found 527.0260; calcd for C₂₇H₂₁Br^{80.9163}O₃K⁺ ([M]+K⁺) = 529.0234, Found 527.0240




	Retention Time	Area	% Area
1	23.084	2873768	17.04
2	27.096	2858535	16.95
3	30.653	5563804	32.99
4	34.829	5569355	33.02




	Retention Time	Area	% Area
1	23.203	1248624	25.80
2	27.271	62418	1.29
3	30.749	3454892	71.39
4	35.149	73470	1.52

(5a*S*,8a*R*,9*S*)-9-(4-methoxyphenyl)-8-(4-methylbenzylidene)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6e) :




Prepared according to the general procedure, Condition B. The title compound **6e** was obtained as yellow oil in 31.4 mg, 94% yield, *E/Z* = 2.3:1, 92/89% ee. SFC (Chiralcel Lux 5 μ Cellulose-1, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 18.11 min, *t*₂ = 23.06 min, *t*₃ = 24.54 min, *t*₄ = 28.84 min, *t*₅ = 30.73 min, *t*₆ = 33.08 min. ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 8.0 Hz, 0.80H), 7.22 (d, *J* = 8.0 Hz,

0.80H), 7.17 – 7.12 (m, 1.27H), 7.09 (d, *J* = 8.0 Hz, 1.23H), 7.04 – 6.98 (m 1H), 6.79 – 6.74 (m, 0.78H), 6.72 – 6.66 (m, 1.23H), 6.65 – 6.58 (m, 2.19H), 6.57 – 6.50 (m, 1.16H), 6.26 (s, 0.41H), 6.20 – 6.12 (m, 1.40H), 6.08 (s, 0.60H), 5.94 – 5.82 (m, 2H), 5.51 – 5.40 (m, 1H), 4.25 (d, *J* = 7.6 Hz, 0.39H), 4.18 (d, *J* = 7.6 Hz, 0.61H), 4.12 (td, *J* = 7.6, 2.0 Hz, 0.38H), 3.73 (s, 1.85H), 3.69 (s, 1.15H), 3.61 (td, *J* = 7.6, 1.2 Hz, 0.61H), 2.43 (s, 1.14H), 2.33 (s, 1.85H). ¹³C NMR (101 MHz, CDCl₃) δ = 158.0, 157.8, 149.7, 149.2, 146.8, 146.7, 145.7, 144.5, 142.3, 139.9, 138.3, 136.6, 136.2, 134.9, 134.8, 134.5, 134.3, 132.8, 132.0, 130.9, 130.1, 129.4, 129.0, 128.2, 128.0, 123.7, 123.4, 123.3, 123.1, 112.8, 112.5, 108.1, 107.8, 100.9, 100.4, 100.2, 85.3, 83.3, 55.1, 55.0, 49.2, 46.2, 45.4, 42.5, 21.3, 21.1. IR $\tilde{\nu}$ (film): 2920, 1508, 1477, 1249, 1182, 1145, 1068, 1039, 941, 867. HRMS (ESI-TOF) calcd for C₂₈H₂₄O₄K⁺ ([M]⁺+K⁺) = 463.1306, Found 463.1305.




	Retention Time	Area	% Area
1	18.116	533078	18.30
2	23.063	705648	24.22
3	24.546	557818	19.15
4	28.844	207823	7.13
5	30.733	204823	7.03

6	33.080	704316	24.17
---	--------	--------	-------




	Retention Time	Area	% Area
1	18.616	476198	1.87
2	23.912	722112	2.84
3	25.501	7960364	31.31
4	32.652	16265390	63.98


(5*S*,8*aR*,9*S*)-9-(4-methoxyphenyl)-8-(2-methylbenzylidene)-5*a*,8,8*a*,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6*f*) :



Prepared according to the general procedure, Condition B. The title compound **6f** was obtained as yellow oil in 35.2 mg, 83% yield, *E/Z* = 4:1, 92/83% ee. SFC (Chiralcel Lux 5 μ Cellulose-1, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) t_1 = 20.24 min, t_2 = 22.69 min, t_3 = 24.86 min, t_4 = 30.61 min. ¹H NMR (400 MHz, CDCl₃) δ 7.56 – 7.49 (m, 0.3H), 7.25 – 7.16 (m, 2H), 7.14 – 7.05 (m, 2H), 6.96-6.91 (m, 0.8H), 6.74-6.66 (m, 2H), 6.65 (s, 0.76H), 6.61 (s, 0.74H), 6.56 (s, 0.26H), 6.54-6.52 (m, 0.28H), 6.52-6.50 (m, 0.23H), 6.49-6.45 (m, 0.78H), 6.43 (s, 0.24H), 6.41-6.37 (m, 0.26H), 6.31 – 6.19 (m, 2H), 5.90 (d, *J* = 1.2 Hz, 0.79H), 5.88-5.84 (m, 1H), 5.79 (d, *J* = 1.2 Hz, 0.23H), 5.45 – 5.37 (m, 1H), 4.28 – 4.18 (m, 1H), 3.95 – 3.90 (m, 0.27H), 3.77 – 3.66 (m, 3.85H), 2.13 (s, 2.34H), 1.92 (s, 0.72H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.0, 157.8, 149.7, 149.1, 146.8, 146.7, 146.6, 145.7, 142.4, 140.7, 137.8, 137.2, 136.9, 136.7, 136.1, 135.0, 134.5, 134.2, 133.2, 130.5, 130.1, 129.8, 129.4, 129.0, 127.1, 127.1, 126.8, 125.8, 125.5, 124.7, 123.9, 122.0, 113.0, 112.7, 108.0, 107.9, 101.0, 100.9, 100.5, 100.45, 85.2, 83.7, 55.1, 48.1, 46.3, 44.1, 43.4, 19.9. IR $\tilde{\nu}$ (film): 3064, 2916, 1508, 1475, 1251, 1182, 1147, 1035, 937, 752. HRMS (ESI-TOF) calcd for C₂₈H₂₄O₄K⁺ ([M]⁺+K⁺) = 463.1306, Found 463.1313.




	Retention Time	Area	% Area
1	20.240	1682133	12.82
2	22.686	5417117	41.28
3	24.857	1451290	11.06
4	30.609	4571102	34.84




	Retention Time	Area	% Area
1	20.212	236732	1.82
2	22.619	407622	3.14
3	24.670	2596508	19.98
4	30.482	9754739	75.06

(5a*S*,8a*R*,9*S*)-9-(4-methoxyphenyl)-8-(naphthalen-1-ylmethylene)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6g) :




Prepared according to the general procedure, Condition B. The title compound **6g** was obtained as yellow oil in 32.7 mg, 71% yield, *E/Z* = 2.3:1, 96/90% ee. SFC (Chiralcel Lux 5 μ Amylose-2, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) t_1 = 29.92 min, t_2 = 35.79 min, t_3 = 42.34 min, t_4 = 45.49 min. ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.4 Hz, 0.33H), 7.84 (d, *J* = 8.4 Hz, 0.33H), 7.80 (d, *J* = 8.4 Hz, 0.70H), 7.71 (d, *J* = 8.4 Hz, 0.70H), 7.65 – 7.59 (m, 0.66H), 7.55 – 7.49 (m, 0.67H), 7.48 – 7.41 (m, 1.67H), 7.40 – 7.33 (m, 1.51H), 7.33 – 7.27 (m, 1.40H), 7.10 (d, *J* = 6.8 Hz, 0.71H), 6.82 (s, 0.32H), 6.78 – 6.72 (m, 1.41H), 6.69 (s, 0.71H), 6.64 – 6.58 (m, 1.37H), 6.55 (s, 0.29H), 6.51 – 6.46 (m, 0.92H), 6.43 (d, *J* = 6.0 Hz, 1H), 6.35 – 6.30 (m, 0.61H), 6.29 – 6.19 (m, 1.32H), 5.91 (d, *J* = 1.6 Hz, 0.7H), 5.87 (d, *J* = 1.2 Hz, 0.7H), 5.83 (d, *J* = 1.6 Hz, 0.3H), 5.76 (d, *J* = 1.2 Hz, 0.3H), 5.43 (d, *J* = 7.6 Hz, 1H), 4.35 (d, *J* = 8.4 Hz, 0.7H), 4.25 (td, *J* = 8.0, 2.0 Hz, 0H), 3.86 – 3.80 (m, 0.72H), 3.78 – 3.69 (m, 2.41H), 3.62 (s, 0.90H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.2, 157.6, 149.7, 149.1, 148.2, 147.3, 146.7, 146.5, 142.5, 142.3, 140.2, 137.7, 135.5, 135.1, 135.0, 134.9, 133.8, 133.7, 133.6, 133.4, 132.0, 131.7, 130.5, 129.6, 128.3, 128.1, 127.6, 127.2, 126.4, 125.8, 125.6, 125.4, 125.3, 125.2, 125.0, 124.4, 124.1, 121.2, 121.0, 113.3, 112.5, 107.9, 101.0, 100.9, 100.5, 100.3, 99.9, 84.9, 83.8, 55.1, 54.9, 47.9, 46.3, 44.4, 43.3. IR $\tilde{\nu}$ (film): 3059, 2918, 1508, 1475, 1249, 1182, 1145, 1035, 794, 781. HRMS (ESI-TOF) calcd for C₃₁H₂₄O₄K⁺ ([M]⁺+K⁺) = 499.1306, Found 499.1313.




	Retention Time	Area	% Area
1	29.927	5348800	18.49
2	35.789	5272462	18.22
3	42.347	9213630	31.84

4	45.490	9100888	31.45
---	--------	---------	-------



	Retention Time	Area	% Area
1	30.016	1861691	33.14
2	36.153	95385	1.70
3	42.524	3597882	64.04
4	45.772	63477	1.13


(5*aS*,8*aR*,9*S*)-9-(4-methoxyphenyl)-8-(naphthalen-2-ylmethylene)-5*a*,8*a*,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6*h*) :




Prepared according to the general procedure, Condition B.

The title compound **6h** was obtained as yellow oil in 42.1 mg, 92% yield, *E/Z* = 1.5:1, 93/91% ee. SFC (Chiralcel Lux 5μ Amylose-2, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 33.44 min, *t*₂ = 44.14 min, *t*₃ = 49.25 min, *t*₄ = 58.80 min. ¹H NMR (400 MHz, CDCl₃) δ 7.92 – 7.79 (m, 2H), 7.79 – 7.72 (m, 1.44H), 7.59 – 7.40 (m, 3H), 7.27

– 7.25(m, 0.81H), 7.22 – 7.15 (m, 1.16H), 6.77 – 6.68 (m, 2.57H), 6.67 – 6.61 (m, 1.50H), 6.55 – 6.47 (m, 1.24H), 6.45 (s, 0.46H), 6.30 – 6.18 (m, 2H), 5.94 – 5.82 (m, 2H), 5.56 – 5.44 (m, 1H), 4.32 – 4.20 (m, 1.41H), 3.76–3.64 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ = 158.1, 157.8, 149.7, 149.2, 147.1, 146.9, 146.8, 145.7, 142.4, 140.0, 139.1, 135.3, 135.2, 134.3, 133.7, 133.4, 132.8, 132.3, 132.1, 131.9, 131.0, 130.1, 128.2, 127.9, 127.8, 127.7, 127.6, 127.2, 126.7, 126.5, 126.4, 126.3, 126.2, 126.0, 125.7, 123.7, 123.5, 123.3, 123.2, 112.8, 112.5, 108.1, 107.8, 101.0, 100.4, 100.3, 85.3, 83.2, 55.1, 55.0, 49.4, 46.2, 45.6, 42.9. IR $\tilde{\nu}$ (film): 3055, 2902, 1510, 1475, 1251, 1180, 1147, 1043, 1037, 939, 746. HRMS (ESI-TOF) calcd for C₃₁H₂₄O₄K⁺ ([M]⁺+K⁺) = 499.1306, Found 499.1313.




	Retention Time	Area	% Area
1	33.440	3415790	16.14
2	44.147	3167608	14.97
3	49.249	7355674	34.76
4	58.800	7220056	34.12




	Retention Time	Area	% Area
1	33.020	12833337	36.91
2	44.060	629182	1.81
3	48.397	20566503	59.15
4	58.439	738984	2.13

(5a*S*,8a*R*,9*S*)-9-(4-methoxyphenyl)-8-(thiophen-3-ylmethylene)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6i) :




Prepared according to the general procedure, Condition B. The title compound **6i** was obtained as yellow oil in 27.1 mg, 55% yield, *E/Z* = 1:1, 93/93% ee. SFC (Chiralcel Lux 5 μ Amylose-2, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) t_1 = 19.36 min, t_2 = 23.48 min, t_3 = 24.69 min, t_4 = 26.79 min, t_5 = 30.27 min, t_6 = 34.22 min. ¹H NMR (400 MHz, CDCl₃) δ 7.42 - 7.37 (m, 0.5H), 7.26 - 7.21 (m, 1.5H), 7.17 - 7.10 (m, 1H), 6.99 - 6.91 (m, 1H), 6.85 -

6.77 (m, 1H), 6.73 - 6.67 (m, 1H), 6.65 - 6.60 (m, 2H), 6.59 - 6.53 (m, 1H), 6.32 (s, 0.5H), 6.17 (dt, *J* = 5.6, 1.6 Hz, 0H), 6.14 - 6.09 (m, 1H), 6.00 (s, 0.5H), 5.92 - 5.83 (m, 2H), 5.50 - 5.40 (m, 1H), 4.33 (d, *J* = 7.6 Hz, 0.5H), 4.17 (d, *J* = 7.6 Hz, 0.5H), 3.97 (td, *J* = 7.6, 1.6 Hz, 0.5H), 3.73 (s, 1.5H), 3.69 (s, 1.5H), 3.59 (td, *J* = 7.6, 1.6 Hz, 0.5H). ¹³C NMR (101 MHz, CDCl₃) δ = 158.0, 157.8, 149.6, 149.3, 146.9, 146.7, 145.4, 144.4, 142.4, 142.3, 139.2, 139.0, 138.8, 138.3, 135.0, 134.4, 132.5, 131.8, 131.0, 130.2, 127.7, 127.7, 125.9, 125.3, 123.4, 123.3, 122.7, 121.8, 117.3, 112.8, 112.5, 108.1, 107.8, 101.0, 101.0, 100.4, 100.2, 85.2, 83.3, 55.1, 55.0, 49.2, 46.2, 46.0, 42.7. IR $\tilde{\nu}$ (film): 3049, 2916, 1508, 1477, 1249, 1182, 1149, 1064, 1033, 935, 837, 736. HRMS (ESI-TOF) calcd for C₂₅H₂₀O₄SK⁺ ([M]⁺+K⁺) = 455.0714, Found 455.0717.




	Retention Time	Area	% Area
1	19.366	885877	26.03
2	23.484	891957	26.20
3	24.686	75362	2.21
4	26.793	87108	2.56

5	30.272	724191	21.28
6	34.225	739383	21.72




	Retention Time	Area	% Area
1	18.514	2077117	53.78
2	22.603	63384	1.64
3	26.018	1667598	43.18
4	28.073	54116	1.40

(5a*S*,8a*R*,9*S*)-8-(benzo[*b*]thiophen-3-ylmethylene)-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6j) :




Prepared according to the general procedure, Condition B. The title compound **6j** was obtained as yellow oil in 41.9 mg, 90% yield, *E/Z* = 1.2:1, 94/92% ee. SFC (Chiralcel Lux 5 μ Amylose-2, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) t_1 = 35.48 min, t_2 = 42.79 min, t_3 = 52.14 min, t_4 = 57.22 min. ¹H NMR (400 MHz, CDCl₃) δ 7.98 – 7.90 (m, 0.54H), 7.86 – 7.80 (m, 0.46H), 7.63 – 7.57 (m, 0.56H), 7.51 (s, 0.58H), 7.46 – 7.39 (m, 1H), 7.39 – 7.30 (m, 1.46H), 7.26 – 7.20 (m, 1H), 7.05 (d, *J* = 0.4 Hz, 0.46H), 6.75 – 6.69 (m, 1H), 6.68 – 6.63 (m, 1.55H), 6.61 (d, *J* = 6.0 Hz, 1H), 6.57 – 6.53 (m, 0.50H), 6.51 – 6.47 (m, 1H), 6.40 – 6.35 (m, 1H), 6.34 – 6.30 (m, 0.56H), 6.28 – 6.18 (m, 1.47H), 5.92 – 5.80 (m, 2H), 5.50 – 5.42 (m, 1H), 4.30 – 4.21 (m, 1H), 4.11 (td, *J* = 7.6, 1.6 Hz, 1H), 3.77 – 3.70 (m, 1.85H), 3.63 (s, 1.62H). ¹³C NMR (100 MHz, CDCl₃) δ = 158.2, 157.7, 149.6, 149.1, 148.2, 147.4, 146.8, 142.4, 142.4, 139.7, 139.4, 139.0, 138.5, 138.3, 135.6, 135.2, 133.3, 133.2, 132.9, 132.7, 130.8, 129.9, 124.4, 123.9, 123.6, 123.6, 122.7, 122.6, 122.4, 122.1, 122.0, 115.3, 114.8, 113.1, 112.5, 108.1, 107.8, 101.0, 100.5, 100.3, 84.9, 83.6, 55.1, 54.9, 48.5, 46.2, 45.7, 42.3. IR $\tilde{\nu}$ (film): 3066, 2897, 1510, 1477, 1249, 1182, 1147, 1064, 1039, 937, 869, 759, 731. HRMS (ESI-TOF) calcd for C₂₉H₂₂O₄SK⁺ ([M]⁺+K⁺) = 505.0870, Found 505.0880.




	Retention Time	Area	% Area
1	35.480	9887298	27.09

2	42.794	9758360	26.74
3	52.139	8344175	22.86
4	57.215	8510040	23.32




	Retention Time	Area	% Area
1	35.691	12530525	56.55
2	43.735	502172	2.27
3	52.683	8861894	39.99
4	58.554	265032	1.20

(5a*S*,8a*R*,9*S*)-8-(cyclohexylmethylene)-9-(4-methoxyphenyl)-5a,8,8a,9-tetrahydrocyclopenta[*b*][1,3]dioxolo[4,5-*g*]chromene (6k) :




Prepared according to the general procedure, Condition B. The title compound **6k** was obtained as yellow oil in 30.7 mg, 74% yield, *E/Z* = 4:1, 92/79% ee. SFC (Chiralcel Lux 5 μ Cellulose-1, CO₂/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 254 nm) *t*₁ = 12.02 min, *t*₂ = 14.03 min, *t*₃ = 19.43 min, *t*₄ = 21.07 min. ¹H NMR (400 MHz, CDCl₃) δ 7.16 - 7.07 (m, 2H), 6.71 - 6.64 (m, 2H), 6.63 - 6.54 (m, 2H), 6.35 (d, *J* = 5.6 Hz, 0.78H), 6.05 (dd, *J* = 5.6, 0.8 Hz, 0.28H), 6.00 (dt, *J* = 5.6, 2.0 Hz, 1H), 5.96 (dd, *J* = 5.6, 2.0 Hz, 0.24H), 5.90 - 5.86 (m, 1H), 5.84 (d, *J* = 1.2 Hz, 1H), 5.38-5.30 (m, 1H), 5.16 (d, *J* = 9.6 Hz, 0.23H), 4.88 (d, *J* = 9.6 Hz, 0.77H), 4.18 (d, *J* = 8.0 Hz, 0.24H), 4.04 (d, *J* = 8.0 Hz, 0.77H), 3.74 (s, 2.23H), 3.72 (s, 0.67H), 3.61 (td, *J* = 7.6, 1.6 Hz, 0.24H), 3.42 (td, *J* = 7.6, 1.6 Hz, 0.77H), 2.23-2.04 (m, 1H), 1.81 - 1.60 (m, 3H), 1.54 (m, 1H), 1.40 - 1.33 (m, 1H), 1.31 - 1.10 (m, 3H), 1.06 - 0.86 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ = 157.9, 149.7, 149.5, 146.7, 146.6, 142.3, 142.2, 141.0, 138.9, 134.7, 134.1, 133.5, 132.9, 132.7, 130.9, 130.4, 130.0, 129.9, 124.1, 123.9, 112.8, 112.7, 107.8, 100.9, 100.4, 100.3, 85.0, 83.9, 55.1, 55.0, 47.3, 45.9, 45.3, 45.2, 38.7, 38.3, 33.4, 33.2, 32.8, 26.0, 25.9, 25.8, 25.8. IR $\hat{\nu}$ (film): 2922, 2850, 1510, 1477, 1249, 1182, 1145, 1037, 939, 854. HRMS (ESI-TOF) calcd for C₂₇H₂₈O₄K⁺ ([M]⁺+K⁺) = 455.1619, Found 455.1626.





Retention Time	Area	% Area
----------------	------	--------

1	12.022	1478126	12.00
2	14.030	4573911	37.14
3	19.428	4780068	38.82
4	21.065	1481836	12.03



	Retention Time	Area	% Area
1	11.976	255979	1.96
2	13.972	458314	3.51
3	19.440	10195369	77.99
4	21.232	2162934	16.55

5. The X-ray data for **6d**.



The product **6d** was recrystallized from DCM, *i*PrOH and Petroleum ether. CCDC-1569433 (**6d**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

6. Copy of NMR spectra

